



Emergent BioSolutions Sponsors Security and Defence Agenda Roundtable on Biopreparedness

October 14, 2009

BRUSSELS--(BUSINESS WIRE)--Oct. 14, 2009-- Emergent BioSolutions Inc. (NYSE:EBS) was pleased to sponsor the Security and Defence Agenda's (SDA) roundtable discussion, "Raising Biopreparedness Levels in Europe," which examined European efforts in preparing and reacting to various biological threats and the potential for European cooperation in these areas. Attended by officials and experts from the security, defense, and health communities across Europe, the roundtable discussion was designed to elevate awareness among professionals in the European Union (EU) about the importance of biopreparedness against naturally-occurring pandemics and bioterrorist attacks.

The EU is working to find the best formula to assess threats, which requires building confidence mechanisms across borders and allowing for better information exchange between the member states' intelligence services. Panel speakers from NATO, the European Commission, and the Office of the EU counterterrorism coordinator shared their experiences and expressed their views on how to ensure civilian and military safety in Europe. In view of the expected Lisbon Treaty to come into force, the solidarity among European member states is expected to further increase and possible responses could be found in regional approaches.

"Emergent BioSolutions applauds SDA for understanding both the urgency and importance of comprehensive, region-wide biopreparedness," said Allen Shofe, senior vice president for public affairs of Emergent BioSolutions. "The SDA has demonstrated a strong commitment to biopreparedness and bio-related issues since its inception in 2002. Today's roundtable is particularly timely as the European Commission had recently launched its CBRN Action Plan, which provides a solid foundation for increased biopreparedness."

Biopreparedness includes the development of a comprehensive and executable preparedness and response plan well in advance of an actual biological incident. The plan encompasses research and development of medical countermeasures and their subsequent approval and procurement for government stockpiles, authorization of their use, and logistics for transporting and dispensing these medical countermeasures in the event of an attack.

The roundtable discussion was held on October 14, 2009 at the prestigious Bibliothèque Solvay in Brussels, Belgium.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com and www.biothrax.com.

About the Security & Defence Agenda

The Security & Defence Agenda (SDA) is the only specialist Brussels-based think-tank where EU institutions, NATO, national governments, industry, specialised and international media, think tanks, academia and NGOs gather to discuss the future of European and transatlantic security and defence policies in Europe and worldwide.

Building on the combined expertise and authority of those involved in our meetings, the SDA gives greater prominence to the complex questions of how EU and NATO policies can complement one another, and how transatlantic challenges such as terrorism, cybercrime, or proliferation can be met.

By offering a high-level and neutral platform for debate, the SDA sets out to clarify policy positions, stimulate discussion and ensure a wider understanding of defence and security issues by the press and public opinion.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2009, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain new BioThrax® sales contracts; the rate and degree of market acceptance and clinical utility of our products and other factors identified in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Source: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com